This observational study will evaluate data from infants born to HIV infected mothers in
order to better characterize disease progression in early HIV infection.
The role of HIV-specific cytotoxic T-lymphocytes (CTL) in controlling viremia and protecting
against disease progression following vertical infection may be dependent upon CTL
functional responses as well as on the timing of detection, magnitude, and breadth of the
responses. Novel and sensitive assay systems (MHC-peptide tetramers, ELISPOT assays,
intracellular cytokine assays) have enhanced the detection and characterization of
virus-specific CTL responses in the peripheral blood. This study will use these novel
methods to examine the timing of detection, magnitude, specificity, and in vitro functional
properties of HIV-specific CTL in infants; to evaluate the effects of potent combination
antiretroviral therapy on HIV-specific CTL in infants; and to evaluate the immunogenicity of
recombinant pox-based vaccines in HIV infected infants with prolonged viral suppression
following early potent combination antiretroviral therapy.
Blood samples from infants born to HIV infected women will be obtained from infants enrolled
in other HIV trials. Generally, samples will be obtained at birth, Week 1, and Months 1, 2,
4, 6, 9, and 12.
- Infants and children born to HIV infected women